Phase 3 study shows bilastine 0.6% is safe and well-tolerated in children and adolescents, suggesting its potential as an effective treatment.
Preservative- and phosphate-free bilastine 0.6% ophthalmic solution with sodium hyaluronate was safe and well-tolerated in pediatric patients aged >2 years after a once-daily, 8-week treatment, with a safety profile comparable to that of placebo.
No takes yet. Share an insight, caveat, or question.
Garriga-Baraut et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: